Genetics of systemic sclerosis: Recent advances

Current Opinion in Rheumatology

Volumn 27, Issue 6, 2015, Pages 521-529

  Ramos, Paula S ^a   Silver, Richard M ^a   Feghali Bostwick, Carol A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Functional variation; Genetic association; Population genetics

Indexed keywords

ANTINUCLEAR ANTIBODY;

AFRICAN AMERICAN; ALLELE; AUTOIMMUNE DISEASE; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FIRST DEGREE RELATIVE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HERITABILITY; HUMAN; MONOZYGOTIC TWINS; NATURAL SELECTION; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; GENETICS; IMMUNOLOGY;

HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84942511978     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000214     Document Type: Review

References (89)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117:557-567.
2. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am 2008; 34:1-15; v.
3. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205.
4. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24:165-170.
5. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012; 71:1355-1360.
6. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 2002; 81:139-153.
7. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81:154-167.
8. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40:734-742.
9. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48:2246-2255.
10. Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114:801-807.
11. Krishnan E, Furst DE. Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005; 20:855-861.
12. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57:318-326.
13. Nietert PJ, Mitchell HC, Bolster MB, et al. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006; 33:263-268.
14. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944.
15. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012; 337:1190-1195.
16. Hudson M, Rojas-Villarraga A, Coral-Alvarado P, et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008; 31:156-159.
17. Englert H, Small-McMahon J, Chambers P, et al. Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999; 29:36-41.
18. Arora-Singh RK, Assassi S, del Junco DJ, et al. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J Autoimmun 2010; 35:52-57.
19. Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001; 44:1359-1362.
20. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48:1956-1963.
21. Frech T, Khanna D, Markewitz B, et al. Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. Arthritis Rheum 2010; 62:2109-2116.
22. Allanore Y, Saad M, Dieude P, et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 2011; 7:e1002091.
23. Gorlova O, Martin JE, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genomewide association strategy. PLoS Genet 2011; 7:e1002178.
24. Martin JE, Assassi S, Diaz-Gallo LM, et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet 2013; 22:4021-4029.
25. Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 2010; 42:426-429.
26. Mayes MD, Bossini-Castillo L, Gorlova O, et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet 2014;94:47-61.
27. Zochling J, Newell F, Charlesworth JC, et al. An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. Arthritis Res Ther 2014; 16:438.
28. Bossini-Castillo L, Martin JE, Broen J, et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum Mol Genet 2012; 21:926-933.
29. Martin JE, Broen JC, Carmona FD, et al. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study followup. Hum Mol Genet 2012; 21:2825-2835.
30. Bossini-Castillo L, Martin JE, Broen J, et al. Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Ann Rheum Dis 2013; 72:602-607.
31. Lopez-Isac E, Bossini-Castillo L, Guerra SG, et al. Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. Arthritis Rheumatol 2014; 66:3521-3523.
32. Lopez-Isac E, Bossini-Castillo L, Simeon CP, et al. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res Ther 2014; 16:R6.
33. Agarwal SK, Gourh P, Shete S, et al. Association of interleukin 23 receptor polymorphisms with antitopoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J Rheumatol 2009; 36:2715-2723.
34. Rueda B, Broen J, Torres O, et al. The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype. Ann Rheum Dis 2009; 68:253-256.
35. Gourh P, Tan FK, Assassi S, et al. Association of the PTPN22 R620W polymorphismwith antitopoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum 2006; 54:3945-3953.
36. Dieude P, Guedj M, Wipff J, et al. The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum 2008; 58:2183-2188.
37. Diaz-Gallo LM, Gourh P, Broen J, et al. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Ann Rheum Dis 2011; 70:454-462.
38. Dieude P, Boileau C, Guedj M, et al. Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. Ann Rheum Dis 2011; 70:1695-1696.
39. Gourh P, Arnett FC, Tan FK, et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann Rheum Dis 2010; 69:550-555.
40. Bossini-Castillo L, Broen JC, Simeon CP, et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis 2011; 70:638-641.
41. Coustet B, Bouaziz M, Dieude P, et al. Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosis. J Rheumatol 2012; 39:997-1003.
42. Tsuchiya N, Kawasaki A, Hasegawa M, et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum Dis 2009; 68:1375-1376.
43. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009; 18:2071-2077.
44. Gourh P, Agarwal SK, Divecha D, et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009; 60:3794-3806.
45. Dieude P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009; 60:2472-2479.
46. Broen JC, Bossini-Castillo L, van Bon L, et al. A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 2012; 64:264-271.
47. Dieude P, Wipff J, Guedj M, et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum 2009; 60:3447-3454.
48. Rueda B, Gourh P, Broen J, et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 2010; 69:700-705.
49. Dieude P, Guedj M, Wipff J, et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Ann Rheum Dis 2010; 69:1958-1964.
50. Terao C, Ohmura K, Kawaguchi Y, et al. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis Rheum 2013; 65:472-480.
51. Koumakis E, Giraud M, Dieude P, et al. Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum 2012; 64:2746-2752.
52. Koumakis E, Bouaziz M, Dieude P, et al. A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosis. Arthritis Rheum 2013; 65:3202-3208.
53. Ito I, Kawaguchi Y, Kawasaki A, et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009; 60:1845-1850.
54. Dieude P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum 2009; 60:225-233.
55. Dieude P, Dawidowicz K, Guedj M, et al. Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity. J Rheumatol 2010; 37:987-992.
56. Gourh P, Agarwal SK, Martin E, et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun 2010; 34:155-162.
57. Ito I, Kawaguchi Y, Kawasaki A, et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 2010; 62:890-895.
58. Coustet B, Dieude P, Guedj M, et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis. Arthritis Rheum 2011; 63:2091-2096.
59. Martin JE, Carmona FD, Broen JC, et al. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes Immun 2012; 13:191-196.
60. Liakouli V, Manetti M, Pacini A, et al. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis 2009; 68:584-590.
61. Broen J, Gourh P, Rueda B, et al. The FAS -670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes. Arthritis Rheum 2009; 60:3815-3820.
62. Carmona FD, Gutala R, Simeon CP, et al. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis 2012; 71:114-119.
63. Wipff J, Dieude P, Guedj M, et al. Association of a KCNA5 gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. Arthritis Rheum 2010; 62:3093-3100.
64. Dieude P, Guedj M, Wipff J, et al. NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Ann Rheum Dis 2011; 70:668-674.
65. Dieude P, Guedj M, Truchetet ME, et al. Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. Arthritis Rheum2011; 63:1097-1105.
66. Wu SP, Leng L, Feng Z, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum 2006; 54:3661-3669.
67. Bossini-Castillo L, Simeon CP, Beretta L, et al. Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. Rheumatology (Oxford) 2011; 50:1976-1981.
68. Dieude P, Bouaziz M, Guedj M, et al. Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1196Phe/532Ser haplotype. Arthritis Rheum 2011; 63:3979-3987.
69. Carmona FD, Cenit MC, Diaz-Gallo LM, et al. New insight on the Xq28 association with systemic sclerosis. Ann Rheum Dis 2013; 72:2032-2038.
70. Luo Y, Wang Y, Wang Q, et al. Systemic sclerosis: genetics and epigenetics. J Autoimmun 2013; 41:161-167.
71. Martin JE, Bossini-Castillo L, Martin J. Unraveling the genetic component of systemic sclerosis. Hum Genet 2012; 131:1023-1037.
72. Assassi S, Radstake TR, Mayes MD, et al. Genetics of scleroderma: implications for personalized medicine? BMC Med 2013; 11:9.
73. Arismendi M, Giraud M, Ruzehaji N, et al. Identification of NF-kappaB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. Arthritis Res Ther 2015; 17:71.
74. Korman BD, Criswell LA. Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance. Curr Rheumatol Rep 2015; 17:21.
75. Jin J, Chou C, Lima M, et al. Systemic sclerosis is a complex disease associated mainly with immune regulatory and inflammatory genes. Open Rheumatol J 2014; 8:29-42.
76. Altorok N, Almeshal N, Wang Y, et al. Epigenetics, the holy grail in the pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2014. [Epub ahead of print]
77. Broen JC, Radstake TR, Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 2014; 10:671-681.
78. Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014; 66:1967-1978.
79. Mahoney JM, Taroni J, Martyanov V, et al. Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput Biol 2015; 11:e1004005.
80. Hindorff LA, MacArthur J, Morales J, et al. A catalog of published genomewide association studies. www.genome.gov/gwastudies. [Accessed 27 March 2015]
81. Diaz-Gallo LM, Simeon CP, Broen JC, et al. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis 2013; 72:1233-1238.
82. Farh KK, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015; 518:337-343.
83. Rigamonti C, Bogdanos DP, Mytilinaiou MG, et al. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int J Rheumatol 2011; 2011:976427.
84. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, et al. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis 2012; 2012:254319.
85. Corona E, Chen R, Sikora M, et al. Analysis of the genetic basis of disease in the context of worldwide human relationships and migration. PLoS Genet 2013; 9:e1003447.
86. Ramos PS, Shedlock AM, Langefeld CL. Genetics of autoimmune diseases: insights from population genetics. J Hum Genet 2015; doi: 10.1038/jhg.2015.94. [Epub ahead of print]
87. Quintana-Murci L, Clark AG. Population genetic tools for dissecting innate immunity in humans. Nat Rev Immunol 2013; 13:280-293.
88. Thannickal VJ, Zhou Y, Gaggar A, et al. Fibrosis: ultimate and proximate causes. J Clin Invest 2014; 124:4673-4677.
89. Roadmap Epigenomics C, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015; 518:317-330.